Gdańsk Medical University

About: Gdańsk Medical University is a education organization based out in Gdańsk, Poland. It is known for research contribution in the topics: Population & Cancer. The organization has 4893 authors who have published 11216 publications receiving 260523 citations.

Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency

Abstract: Wstep: Wyniki badan z ostatnich lat dokumentują wiele korzyści wynikających z dzialania witaminy D na organizm czlowieka na wszystkichetapach jego zycia Wiekszośc badan epidemiologicznych sugeruje, ze niedobor witaminy D jest powszechny wśrod mieszkancow EuropyŚrodkowej Naturalną konsekwencją tej sytuacji jest koniecznośc ciąglego uświadamiania spoleczenstwu oraz środowisku medycznemu,jaką role odgrywa witamina D w rozwoju i funkcjonowaniu organizmu ludzkiego Metody: Na podstawie przeglądu danych literaturowych Polski Zespol Wielodyscyplinarny opracowal tezy dotyczące zasad suplementacjiwitaminą D, ktore przeslano do czlonkow Komitetu Naukowego konferencji „Witamina D — minimum, maksimum, optimum”,19–20 Październik, 2012, Warszawa W trakcie powyzszej konferencji z udzialem 550 delegatow oraz Ekspertow roznych dziedzin medycynyomowiono i przedyskutowano propozycje wytycznych suplementacji witaminą D populacji Europy Środkowej Wyniki: W efekcie przeprowadzonych dyskusji Zespol Ekspertow opracowal wytyczne suplementacji witaminą D dla wszystkich grupwiekowych populacji Europy Środkowej Określono rowniez kryteria diagnostyczne charakteryzujące stan zaopatrzenia organizmu w witamine D: deficyt witaminy D ustalono jako stezenie 25(OH)D < 20 ng/mL (< 50 nmol/L)], suboptymalne zaopatrzenie jako stezenie25(OH)D wynoszące 20–30 ng/mL (50–75 nmol/L), a stezenie 30–50 ng/mL (75–125 nmol/L) uznano za docelowe dla zapewnienia efektuplejotropowego witaminy D Wnioski: Poprawa obecnego stanu zaopatrzenia witaminy D w grupach dzieci, mlodziezy, osob aktywnych zawodowo i seniorowpowinna zostac wlączona do priorytetow polityki zdrowotnej spoleczenstw Europy Środkowej

Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea

Abstract: Patients with obstructive sleep apnea (OSA) are frequently obese and are predisposed to weight gain. They also have heightened sympathetic drive. We reasoned that noradrenergic activation of β3-receptors on adipocytes would inhibit leptin production, predisposing to obesity in sleep apnea. We therefore tested the hypothesis that obesity and predisposition to weight gain in OSA are associated with low levels of plasma leptin. We prospectively studied 32 male patients (43 ± 2 yr) with OSA who were newly diagnosed and never treated and who were free of any other diseases. Control measurements were obtained from 32 similarly obese closely matched male subjects (38 ± 2 yr). Leptin levels were 13.7 ± 1.3 and 9.2 ± 1.2 ng/ml in patients with OSA and controls, respectively (P = 0.02). Weight gain over the year before diagnosis was 5.2 ± 1.7 and 0.5 ± 0.9 kg in sleep apnea patients and similarly obese control subjects, respectively (P = 0.04). Muscle sympathetic activity was 46 ± 4 and 30 ± 4 bursts/min in patient...

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

Abstract: Objective:Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.Method:In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S).Results:After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms (PANSS: treatment difference=−1.4, 95% CI=−2.5, −0.2) and were more likely to have been rated as improved (CGI-I: treatment difference=−0.5, 95% CI=−0....

European position statement on lung cancer screening

Abstract: Lung cancer screening with low-dose CT can save lives. This European Union (EU) position statement presents the available evidence and the major issues that need to be addressed to ensure the successful implementation of low-dose CT lung cancer screening in Europe. This statement identified specific actions required by the European lung cancer screening community to adopt before the implementation of low-dose CT lung cancer screening. This position statement recommends the following actions: a risk stratification approach should be used for future lung cancer low-dose CT programmes; that individuals who enter screening programmes should be provided with information on the benefits and harms of screening, and smoking cessation should be offered to all current smokers; that management of detected solid nodules should use semi-automatically measured volume and volume-doubling time; that national quality assurance boards should be set up to oversee technical standards; that a lung nodule management pathway should be established and incorporated into clinical practice with a tailored screening approach; that non-calcified baseline lung nodules greater than 300 mm3, and new lung nodules greater than 200 mm3, should be managed in multidisciplinary teams according to this EU position statement recommendations to ensure that patients receive the most appropriate treatment; and planning for implementation of low-dose CT screening should start throughout Europe as soon as possible. European countries need to set a timeline for implementing lung cancer screening.